Stock Price Quote

THYROCARE TECHNOLOGIES LTD.

NSE : THYROCAREBSE : 539871ISIN CODE : INE594H01019Industry : Hospital & Healthcare ServicesHouse : MNC
BSE634.25-9.15 (-1.42 %)
PREV CLOSE ( ) 643.40
OPEN PRICE ( ) 626.20
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1666
TODAY'S LOW / HIGH ( )626.20 644.15
52 WK LOW / HIGH ( )449.95 722
NSE634.90-8.8 (-1.37 %)
PREV CLOSE( ) 643.70
OPEN PRICE ( ) 640.10
BID PRICE (QTY) 634.90 (8)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 30174
TODAY'S LOW / HIGH( ) 632.10 645.95
52 WK LOW / HIGH ( )448 722.65
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-01 2000
Management Info
- Chairman - Managing Director
Registered Office

Address D - 37/1, T T C Industrial Area,M I D C,Turbhe,
Navi Mumbai,
Maharashtra-400703

Phone 022 3090 0000 / 2762 2762

Email investor_relations@thyrocare.com / enquiry@thyrocare.com

Website www.thyrocare.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

14May Thyrocare Technologies informs about o
In continuation of prior intimation dated May 07, 2024, regarding holdin..
28Feb Torrent Power, Infosys and UGRO Capita
Torrent Power has emerged as the Successful Bidder and has received Lett..
28Feb Thyrocare Technologies completes acqui
Thyrocare Technologies has completed the acquisition by way purchase of..
28Feb Thyrocare Technologies jumps on comple
Thyrocare Technologies is currently trading at Rs. 717.15, up by 75.35 p..
23Feb Thyrocare Technologies informs about a
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit192.3711.4
Gross Profit 250.5 982.2
Operating Profit 3641410.6
Net Sales 1412.35240.2

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kovai Medical Center (BSE)
peergroup  4625.35 (13.73%)
M.Cap ( in Cr)5061.18
Metropolis Health. (BSE)
peergroup  1904.30 (3.59%)
M.Cap ( in Cr)9755.50
Dr. Lal Pathlabs (BSE)
peergroup  2555.05 (0.76%)
M.Cap ( in Cr)21329.65
Aster DM Healthcare (BSE)
peergroup  359.35 (3.31%)
M.Cap ( in Cr)17950.00
Fortis Healthcare (BSE)
peergroup  462.25 (2.22%)
M.Cap ( in Cr)34897.94

Shareholding Pattern

PROMOTERS 71.11%
MUTUAL FUNDS/UTI 12.94%
NON-INSTITUTION 11.1%
FI/BANKS/INSURANCE 1.08%
GOVERNMENT 0%
FII 0%

About Thyrocare Technologies Ltd.

Thyrocare Technologies Ltd. was incorporated in the year 2000. Its today's share price is 634.25. Its current market capitalisation stands at Rs 3358.52 Cr. In the latest quarter, company has reported Gross Sales of Rs. 4864.6 Cr and Total Income of Rs.4918.5 Cr. The company's management includes Harshil Jiten Vora, Prapti Ishwar Gilada, Neetin Desai, Indumati Gopinathan, G S Hegde, Dhaval Shah, Hardik Dedhia, Dharmil Sheth.

It is listed on the BSE with a BSE Code of 539871 , NSE with an NSE Symbol of THYROCARE and ISIN of INE594H01019. It's Registered office is at D - 37/1, T T C Industrial Area,M I D C,TurbheNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co, BSR & Co LLP, MSKA & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.